Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of M0324 (MUC-1 x CD40) as Monotherapy and in Combination with Pembrolizumab or mFOLFIRINOX in Advanced Solid Tumors
jRCT2031250509Phase 1Recruiting
- Sponsor
- Merck KGaA
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of M0324 in Nonhematologic neoplasms and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Merck KGaA. Primary endpoints: Dose Limiting Toxicities (DLTs) in Parts 1 and 2, Treatment-Emergent Adverse Events (TEAEs) in Parts 1, 2 and 3 and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
M0324
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031250509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250509.